biotech ipo Value Creation And Destruction: Dispersion of Performance In Biotech IPOs By feedproxy.google.com Published On :: Fri, 17 Apr 2020 11:24:39 +0000 The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. And the queue for companies with active S1’s on file is The post Value Creation And Destruction: Dispersion of Performance In Biotech IPOs appeared first on LifeSciVC. Full Article Biotech financing Capital markets Exits IPOs M&As Biotech IPO Biotech venture capital IPO
biotech ipo Ra makes nine Mass. biotech IPOs, over $640M raised, this year By www.bizjournals.com Published On :: Thu, 27 Oct 2016 09:50:20 +0000 Wednesday’s initial public offering for Cambridge-based Ra Pharmaceuticals marked the ninth biotech startup to go public this year, tying the number in 2013 but still less than either of the two years since. Ra (Nasdaq: RARX), which has 40 employees in one of the former Pfizer buildings in Alewife, ended up with the third-largest IPO size for any Massachusetts-based biotech in 2016, with a total of $92 million raised from the sale of 7 million shares for $13 each. That’s more than the $86 million… Full Article
biotech ipo Biotech IPOs off to a strong start in 2020 By feedproxy.google.com Published On :: 20 Feb 2020 23:49:34 +0000 4 firms have raised more than double their initial expectations Full Article
